These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 27245123)

  • 1. Edge-to-Edge Technique to Minimize Ovelapping of Multiple Bioresorbable Scaffolds Plus Drug Eluting Stents in Revascularization of Long Diffuse Left Anterior Descending Coronary Artery Disease.
    Rigatelli G; Avvocata FD; Ronco F; Giordan M; Roncon L; Caprioglio F; Grassi G; Faggian G; Cardaioli P
    J Interv Cardiol; 2016 Jun; 29(3):275-84. PubMed ID: 27245123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds.
    Puricel S; Arroyo D; Corpataux N; Baeriswyl G; Lehmann S; Kallinikou Z; Muller O; Allard L; Stauffer JC; Togni M; Goy JJ; Cook S
    J Am Coll Cardiol; 2015 Mar; 65(8):791-801. PubMed ID: 25720622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of bioresorbable vascular scaffold Absorb BVS® in patients with stable coronary artery disease: one-year results with special focus on the hybrid bioresorbable vascular scaffolds and drug eluting stents treatment.
    Gil RJ; Bil J; Pawłowski T; Yuldashev N; Kołakowski L; Jańczak J; Jabłoński W; Paliński P
    Kardiol Pol; 2016; 74(7):627-33. PubMed ID: 26779846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of potential substrates for restenosis and thrombosis in overlapped versus edge-to-edge juxtaposed bioabsorbable scaffolds: Insights from a computed fluid dynamic study.
    Rigatelli G; Zuin M; Dell'Avvocata F; Cardaioli P; Vassiliev D; Ferenc M; Nghia NT; Nguyen T; Foin N
    Cardiovasc Revasc Med; 2018 Apr; 19(3 Pt A):273-278. PubMed ID: 28918876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Clinical Outcomes After Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary In-Stent Restenosis: A Multicenter Italian Experience.
    Moscarella E; Ielasi A; Granata F; Coscarelli S; Stabile E; Latib A; Cortese B; Tespili M; Tanaka A; Capozzolo C; Caliendo L; Colombo A; Varricchio A
    Circ Cardiovasc Interv; 2016 Apr; 9(4):e003148. PubMed ID: 27059683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and angiographic outcome of a single center, real world population treated with a dedicated technique of implantation for bioresorbable vascular scaffolds. The FAtebenefratelli Bioresorbable Vascular Scaffold (FABS) registry.
    Cortese B; di Palma G; Cerrato E; Latini RA; Elwany M; Orrego PS; Seregni RG
    J Interv Cardiol; 2017 Oct; 30(5):427-432. PubMed ID: 28853189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hybrid metal/scaffold-jacket versus full-metal jackets in left anterior descending coronary artery diffuse disease: Differences in radiation exposure and fluoroscopic/procedural times.
    Rigatelli G; Zuin M; Frigato J; Dell'Avvocata F; Ronco F; Mazza A; Oliva L; Adami D; Bedendo E; Stefano P
    Cardiovasc Revasc Med; 2017 Dec; 18(8):592-595. PubMed ID: 28546035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial.
    Onuma Y; Dudek D; Thuesen L; Webster M; Nieman K; Garcia-Garcia HM; Ormiston JA; Serruys PW
    JACC Cardiovasc Interv; 2013 Oct; 6(10):999-1009. PubMed ID: 24156961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraindividual Comparison of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Drug-Eluting Metallic Stents.
    Cassese S; Hoppmann P; Kufner S; Byrne RA; Wiebe J; Colleran R; Giacoppo D; Harada Y; Laugwitz KL; Schunkert H; Fusaro M; Kastrati A
    Circ Cardiovasc Interv; 2016 Aug; 9(8):. PubMed ID: 27512088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A hybrid strategy with bioresorbable vascular scaffolds and drug eluting stents for treating complex coronary lesions.
    Jabbour RJ; Ielasi A; Tanaka A; Leoncini M; Cortese B; Grigis G; Mitomo S; Regazzoli D; Di Palma G; Rapetto C; Tespili M; Colombo A; Latib A
    Cardiovasc Revasc Med; 2017; 18(5S1):S4-S9. PubMed ID: 28314675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiographic and clinical outcomes after implantation of drug eluting stents in bifurcation lesions with crush or kissing stent technique.
    Cheema AN; Jolly SS; Burstein JM; Sharieff W; Mohammad A; Yeoh E; Mancini GB; Cantor WJ; Kutryk MJ; Strauss BH; Chisholm RJ
    J Interv Cardiol; 2013 Apr; 26(2):145-52. PubMed ID: 23406435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple overlapping drug-eluting stents to treat diffuse disease of the left anterior descending coronary artery.
    Tsagalou E; Chieffo A; Iakovou I; Ge L; Sangiorgi GM; Corvaja N; Airoldi F; Montorfano M; Michev I; Colombo A
    J Am Coll Cardiol; 2005 May; 45(10):1570-3. PubMed ID: 15893168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mid- to long-term outcome of patients treated with everolimus-eluting bioresorbable vascular scaffolds: Data of the BVS registry Göttingen predominantly from ACS patients.
    Hellenkamp K; Becker A; Gabriel YD; Hasenfuß G; Hünlich M; Jacobshagen C; Schillinger W; Schroeter MR
    Int J Cardiol; 2017 May; 234():58-63. PubMed ID: 28258843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiographic and clinical outcomes of patients treated with everolimus-eluting bioresorbable stents in routine clinical practice: Results of the ISAR-ABSORB registry.
    Hoppmann P; Kufner S; Cassese S; Wiebe J; Schneider S; Pinieck S; Scheler L; Bernlochner I; Joner M; Schunkert H; Laugwitz KL; Kastrati A; Byrne RA
    Catheter Cardiovasc Interv; 2016 Apr; 87(5):822-9. PubMed ID: 26708019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Four-Year Outcomes of Left Main Percutaneous Coronary Intervention with a Bioresorbable Scaffold in the Circumflex Ostium.
    Erglis A; Narbute I; Sondore D; Jegere S; Kumsars I; Dombrovskis A; Grikis K; Briede I; Dombrovska K; Trusinskis K; Grave A; Erglis M; Kalejs M; Stradins P; Strazdins U
    J Interv Cardiol; 2022; 2022():7934868. PubMed ID: 36407753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial.
    Onuma Y; Sotomi Y; Shiomi H; Ozaki Y; Namiki A; Yasuda S; Ueno T; Ando K; Furuya J; Igarashi K; Kozuma K; Tanabe K; Kusano H; Rapoza R; Popma JJ; Stone GW; Simonton C; Serruys PW; Kimura T
    EuroIntervention; 2016 Oct; 12(9):1090-1101. PubMed ID: 27597270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transradial experience with bioresorbable vascular scaffolds: A case-matched study with metallic drug-eluting stents.
    Maes F; Costerousse O; Cieza T; Henry M; Déry JP; Barbeau G; Delarochellière R; Paradis JM; Larose E; Nguyen CM; Pirlet C; Mongrain R; Bertrand OF
    Cardiovasc Revasc Med; 2018 Sep; 19(6):700-704. PubMed ID: 29398632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term clinical outcome of rotational atherectomy followed by drug-eluting stent implantation in complex calcified coronary lesions.
    Abdel-Wahab M; Baev R; Dieker P; Kassner G; Khattab AA; Toelg R; Sulimov D; Geist V; Richardt G
    Catheter Cardiovasc Interv; 2013 Feb; 81(2):285-91. PubMed ID: 22431433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twelve-Month Outcomes With a Bioresorbable Everolimus-Eluting Scaffold: Results of the ESHC-BVS Registry at Two Australian Centers.
    Robaei D; Back L; Ooi SY; Pitney M; Jepson N
    J Invasive Cardiol; 2016 Aug; 28(8):316-22. PubMed ID: 26567454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.